Akanda Corp. (AKAN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Jun 9, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AKAN SEC filings page.
Akanda Corp. (AKAN) reported $258K in revenue for fiscal year 2025, down 69.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business remains dependent on new financing because cash outflows persist while liabilities exceed assets.
In FY2025, operating cash flow was negative at$6.7M while financing provided$11.7M . That financing-dependent pattern was already visible in FY2024, and the shift from$4.3M positive equity to$12.0M negative equity indicates worsening financial support from the balance sheet, not simply a reported earnings fluctuation.
Reported revenue fell to
FY2025 liabilities reached
Financial Health Signals
Akanda Corp. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Akanda Corp. passes 1 of 5 computable financial strength tests (4 of the nine could not be computed from available data). No profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
Akanda Corp. held $2.5M in cash against $71K in long-term debt as of Q4 2025, with $2.8M of liabilities due within a year.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
AKAN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
AKAN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'256-K | Q2'256-K | Q4'2410-K | Q2'2410-K | Q2'2310-K | Q4'2210-K | Q2'2210-K | Q2'2110-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.2M-37.6% | $7.9M-10.5% | $10.0M | $8.8M-77.3% | $39.0M+384.7% | $43.5M | $8.0M+88.2% | $4.3M |
| Current Assets | $3.6M-53.2% | $5.1M+180.0% | $7.6M | $1.8M-52.7% | $3.8M-4.0% | $6.9M | $4.0M+3019.3% | $128K |
| Cash & Equivalents | $2.5M-58.1% | $3.8M+3992.5% | $6.0M | $94K-63.3% | $256K-92.7% | $3.9M | $3.5M+25784.1% | $14K |
| Inventory | N/A | N/A | N/A | $1.3M+21.7% | $1.1M | $896K | N/A | $611 |
| Accounts Receivable | $4K-98.7% | $371K+30.2% | $312K | $285K-77.0% | $1.2M+409.8% | $727K | $242K | N/A |
| Total Liabilities | $2.9M-46.0% | $3.6M-71.3% | $5.4M | $12.7M+4.7% | $12.1M+18.0% | $8.8M | $10.2M+10.1% | $9.3M |
| Current Liabilities | $2.8M-47.3% | $3.6M-64.2% | $5.4M | $10.2M+8.8% | $9.3M+13.1% | $6.3M | $8.3M+202.7% | $2.7M |
| Non-Current Liabilities | $71K | $0-100.0% | $0 | $2.5M-9.2% | $2.7M+38.9% | $2.6M | $2.0M-69.9% | $6.6M |
| Long-Term Debt | $71K | $30K | N/A | N/A | $117K-94.1% | N/A | $2.0M-23.8% | $2.6M |
| Total Equity | $3.3M-27.8% | $4.3M+211.7% | $4.6M | -$3.8M-114.2% | $26.9M+1321.9% | $34.6M | -$2.2M+56.3% | -$5.0M |
| Retained Earnings | -$58.3M-3.9% | -$57.5M-7.7% | -$56.0M | -$53.4M-153.0% | -$21.1M-58.6% | -$12.0M | -$13.3M-157.5% | -$5.2M |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Goodwill.
AKAN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
AKAN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$12.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.58), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Akanda Corp. AKAN | FY2025 | $258K | N/A | N/A | $4.6M | — |
| Universe Pharmaceuticals Inc. UPC | FY2025 | $17.9M | -$3.7M | -20.6% | $21.0M | 46/100 |
| PRF Technologies Ltd. PRFX | FY2025 | $17K | -$5.0M | N/A | $3.0M | — |
| Shuttle Pharmaceuticals Holdings, Inc. SHPH | FY2025 | N/A | -$11.7M | N/A | $26.4M | — |
| Redhill Biopharma Ltd. RDHL | FY2025 | $286K | -$429K | N/A | $5.1M | — |
| InMed Pharmaceuticals Inc. INM | FY2026 | N/A | -$12.6M | N/A | $7.3M | — |
Where Akanda Corp. Ranks
Frequently Asked Questions
What is Akanda Corp.'s annual revenue?
Akanda Corp. (AKAN) reported $258K in total revenue for fiscal year 2025. This represents a -69.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Akanda Corp.'s revenue growing?
Akanda Corp. (AKAN) revenue declined by 69.2% year-over-year, from $837K to $258K in fiscal year 2025.
How much debt does Akanda Corp. have?
As of fiscal year 2025, Akanda Corp. (AKAN) had $3.8M in cash and equivalents against $209K in long-term debt.
What is Akanda Corp.'s free cash flow?
Akanda Corp. (AKAN) recorded an outflow of $8.0M in free cash flow during fiscal year 2025. This represents a -31.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Akanda Corp.'s operating cash flow?
Akanda Corp. (AKAN) recorded an outflow of $6.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Akanda Corp.'s total assets?
Akanda Corp. (AKAN) had $6.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Akanda Corp.'s capital expenditures?
Akanda Corp. (AKAN) invested $1.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Akanda Corp.'s current ratio?
Akanda Corp. (AKAN) had a current ratio of 0.58 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Akanda Corp.'s P/E ratio?
Akanda Corp. (AKAN) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $4.6M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Akanda Corp.'s price-to-sales ratio?
Akanda Corp. (AKAN) trades at 18.0x sales, its market capitalization divided by revenue of $258K revenue, FY2025. The market capitalization is $4.6M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Akanda Corp.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Akanda Corp. (AKAN) held $3.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $6.7M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Akanda Corp.'s debt-to-equity ratio negative or not reported?
Akanda Corp. (AKAN) has negative shareholder equity of -$12.0M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Akanda Corp.'s Piotroski F-Score?
Akanda Corp. (AKAN) has a Piotroski F-Score of 1 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.